Heparan sulphate proteoglycan and the low-density lipoprotein receptor-related protein 1 by Kanekiyo, Takahisa et al.




Heparan sulphate proteoglycan and the low-density
lipoprotein receptor-related protein 1
Takahisa Kanekiyo
Washington University School of Medicine in St. Louis
Juan Zhang
Washington University School of Medicine in St. Louis
Qiang Liu
Washington University School of Medicine in St. Louis
Chia-Chen Liu
Washington University School of Medicine in St. Louis
Lijuan Zhang
Washington University School of Medicine in St. Louis
See next page for additional authors
Follow this and additional works at: http://digitalcommons.wustl.edu/open_access_pubs
Part of the Medicine and Health Sciences Commons
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Kanekiyo, Takahisa; Zhang, Juan; Liu, Qiang; Liu, Chia-Chen; Zhang, Lijuan; and Bu, Guojun, ,"Heparan sulphate proteoglycan and
the low-density lipoprotein receptor-related protein 1." The Journal of Neuroscience.31,5. 1644-1651. (2011).
http://digitalcommons.wustl.edu/open_access_pubs/225
Authors
Takahisa Kanekiyo, Juan Zhang, Qiang Liu, Chia-Chen Liu, Lijuan Zhang, and Guojun Bu
This open access publication is available at Digital Commons@Becker: http://digitalcommons.wustl.edu/open_access_pubs/225
Neurobiology of Disease
Heparan Sulphate Proteoglycan and the Low-Density
Lipoprotein Receptor-Related Protein 1 Constitute Major
Pathways for Neuronal Amyloid- Uptake
Takahisa Kanekiyo,1,5 Juan Zhang,1 Qiang Liu,1 Chia-Chen Liu,1,5 Lijuan Zhang,2 and Guojun Bu1,3,4,5,6
Departments of 1Pediatrics, 2Pathology and Immunology, and 3Cell Biology and Physiology and 4Hope Center for Neurological Disorders, Washington
University School of Medicine, St. Louis, Missouri 63110, 5Department of Neuroscience, Mayo Clinic, Jacksonville, Florida 32224, and 6Institute for
Biomedical Science, Xiamen University, Xiamen 361005, China
Alzheimer’s disease (AD) is a progressive and irreversible neurodegenerative disorder in which the aggregation and deposition of
amyloid- (A) peptides in the brain are central to its pathogenesis. In healthy brains, A is effectively metabolized with little accumu-
lation. Cellular uptake and subsequent degradation of A is one of themajor pathways for its clearance in the brain. Increasing evidence
has demonstrated significant roles for the low-density lipoprotein receptor-related protein 1 (LRP1) in themetabolismofA in neurons,
glia cells, and along the brain vasculatures. Heparan sulfate proteoglycan (HSPG) has also been implicated in several pathogenic features
of AD, including its colocalization with amyloid plaques. Here, we demonstrate that HSPG and LRP1 cooperatively mediate cellular A
uptake. Fluorescence-activated cell sorter and confocal microscopy revealed that knockdown of LRP1 suppresses A uptake, whereas
overexpression of LRP1 enhances this process in neuronal cells. Heparin, which antagonizes HSPG, significantly inhibited cellular A
uptake. Importantly, treatment with heparin or heparinase blocked LRP1-mediated cellular uptake of A.We further showed that HSPG
is more important for the binding of A to the cell surface than LRP1. The critical roles of HSPG in cellular A binding and uptake were
confirmed inChinese hamster ovary cells genetically deficient inHSPG.Wealso showed that heparin and aneutralizing antibody to LRP1
suppressed A uptake in primary neurons. Our findings demonstrate that LRP1 andHSPG function in a cooperativemanner tomediate
cellular A uptake and define a major pathway through which A gains entry to neuronal cells.
Introduction
Alzheimer’s disease (AD) is the most common form of dementia
with amyloid plaques and neurofibrillary tangles as its patholog-
ical hallmarks (Selkoe, 2001, 2002). Increasing evidence supports
the hypothesis that accumulation, aggregation, and deposition of
amyloid- (A) peptides in the brain are critical steps in its
pathogenesis (Selkoe, 2001; Shankar and Walsh, 2009). A pep-
tide is cleaved from amyloid precursor protein (APP) and
secreted into the extracellular space (Bredesen, 2009). It is ef-
fectively cleared in healthy brains (Bu, 2009). In vivomicrodialy-
sis analysis demonstrated that A in brain interstitial fluid of
young mice is cleared within a relatively short half-life (2 h)
(Cirrito et al., 2003). There are several pathways through which
A is cleared from the brain. These include cellular uptake and
degradation, clearance along the interstitial fluid drainage path-
way, through the blood–brain barrier, and through proteolytic
degradation by A-degrading enzymes (Bu, 2009). Members of
the low-density lipoprotein (LDL) receptor family are expressed
in different cell types in these pathways and play important roles
in A clearance. In particular, the LDL receptor-related protein 1
(LRP1) is shown to mediate the metabolism of A in neurons
(Qiu et al., 1999), glia cells (Wyss-Coray et al., 2003), and brain
vessels (Urmoneit et al., 1997; Kanekiyo and Bu, 2009). LRP1 is a
large endocytic receptor that recognizes an array of ligands, in-
cluding APP, apolipoprotein E (apoE), 2-macroglobulin, and
receptor-associated protein (RAP), which are involved in A
production and clearance (Herz and Strickland, 2001; Bu et al.,
2006; Kanekiyo and Bu, 2009). Among these LRP1 ligands, an
isoform of apoE (apoE4) is a strong genetic risk factor for AD
(Bu, 2009).
Heparan sulfate proteoglycans (HSPGs) are abundant cell
surface receptors that interact with a variety of ligands through
electrostatic interactions (Poon and Garie´py, 2007). Several
HSPGs colocalize with senile plaques and cerebral amyloid angi-
opathy (vanHorssen et al., 2003). HSPGs found on the surface of
almost all mammalian cells are members of the glycosaminogly-
can family of polysaccharides and are involved in a large number
of biological processes, including development, embryogenesis,
cell growth and division, homeostasis, and coagulation (Turnbull
et al., 2001). Heparan sulfate (HS) binds to A (Brunden et al.,
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1993) and heparin attenuates neurotoxicity and inflammatory
activity of A, suggesting a potentially important role for HSPG
in cellular metabolism of A (Bergamaschini et al., 2002). In
addition, LRP1 and HSPG are part of an immunoprecipitable
complex at the cell surface to mediate lipid metabolism (Wilsie
andOrlando, 2003). Internalization of apoE/lipoprotein particles
is partially dependent on the HSPG and LRP1 complex (Mahley
and Ji, 1999), suggesting a cooperative function for these apoE
receptors at the cell surface.
Although A clearance by its degrading enzymes has been
studied extensively, less is known about receptor-mediated endo-
cytic pathways for cellularAuptake. In this study,we focused on
both individual and potentially cooperative roles of LRP1 and
HSPG in cellular A uptake. We demonstrated that LRP1 and
HSPG play critical, cooperative roles in neuronal A uptake.
Materials andMethods
Reagents. 5(6)-Carboxyfluorescein (FAM)–A40 and FAM–A42 were
purchased fromAnaSpec. A peptides were dissolved in dimethylsulfox-
ide at 200 M and kept at 80°C before use. Recombinant RAP was
purified as described previously (Warshawsky et al., 1993) and labeled
using the Alexa Fluor 488 Protein Labeling kit (Invitrogen). Anti-LRP1
antibody was produced in-house using rabbit polyclonal antibodies (Liu
et al., 2007). Heparin was purchased from Elkins-Sinn.
Cell culture. Mouse hypothalamic neuronal GT1-7 cells and mouse
embryonic fibroblast (MEF) cells were cultured inDMEMsupplemented
with 10% fetal bovine serum (FBS) andmaintained at 37°C in humidified
air containing 5% CO2. Mouse neuroblastoma N2a cells were stably
transfected with empty vector plasmid (pcDNA3) or mLRP4 plasmid
andmaintained inDMEM/OPTIMEM (1:1) containing 5%FBSwith the
addition of 200 g/ml G418. Chinese hamster ovary (CHO) cells were
grown in Ham’s F-12 medium containing 10% FBS, 100 U/ml penicillin
G, and 100 g/ml streptomycin sulfate. Primary cortical neurons were
obtained from 17-d-old embryos of wild-type mice and grown in
Neurobasal medium (Invitrogen) supplemented with 0.5 mM Glu-
tamax (Invitrogen), 25 M glutamate (Invitrogen), and B27 (Invitro-
gen) (Fuentealba et al., 2009).
LRP1 knockdown by small interfering RNA. Single-stranded, mouse
LRP1-specific sense (5-GGA GUC ACU UAC AUC AAU AUU-3) and
antisense (5-UAUUGAUGUAAGUGA CUCCUU-3) RNA oligonu-
cleotides were synthesized by Dharmacon. Double-stranded RNAmole-
cules were generated according to the instructions of the manufacturer.
Cells were transfected with small interfering RNA (siRNA) (50 nM) using
Lipofectamine2000 (Invitrogen), according to the specifications of the
manufacturer, and analyzed 48 h after transfection. In some experi-
ments, pcDNA3 vector or mLRP4 plasmid was cotransfected with
LRP1–siRNA using Lipofectamine2000 according to the specifica-
tions of the manufacturer.
Confocal microscopy.Cells were cultured on eight-well slides (Lab-Tek
II Chamber SlideTM System; Nalge Nunc International) at 37°C for at
least 24 h before experiments. After incubation with FAM–A40 or
FAM–A42 (500 nM) at 37°C for 4 or 24 h in the presence or absence of
heparin (15 U/ml), fluorescence associated with A was observed by
confocal laser-scanning fluorescence microscopy (model LSM 510 in-
vert; Carl Zeiss). In some experiments, non-immune IgG or anti-LRP1
IgG (75g/ml) was added 1 h before A treatment. LysoTracker (50 nM;
Invitrogen) was added 30 min before cell fixation and confocal imaging.
Fluorescence-activated cell sorter-based internalization and binding as-
says. Cells were plated onto 12-well dishes and allowed to grow to 90%
confluency. Cells were incubated with FAM–A40 (500 nM), FAM–A42
(500 nM), or Alexa Fluor 488–RAP (20 nM) in the presence or absence of
heparin at 37°C for 24 h in DMEM with 10% FBS for internalization
assay. In some experiments, cells were incubated with 5 Sigma U/ml
Heparinase I (product number H2519, lot number 087K3790; Sigma) (Ji
et al., 1998; Wilsie and Orlando, 2003) for 2 h at 37°C in DMEM. Cells
were removed from the plate using Cell Dissociation Solution (Sigma)
and incubatedwith Pronase (0.5mg/ml; RocheDiagnostics) at 4°C for 20
min. Cells were then washed and resuspended in PBS containing 1.5%
FBS, 1% sodium azide, and 1% paraformaldehyde. Cells (1 104) from
each sample were analyzed for fluorescence on a BD FACS Calibur ma-
chine (BDBiosciences). Unstained cells without any exposure to fluores-
cence were used as a control for background fluorescence. Mouse
primary cortical neurons were incubated with FAM–A42 (500 nM) in
the presence or absence of heparin at 37°C for 1, 4, 8, or 24 h. Non-
immune IgG or anti-LRP1 IgG (75 g/ml) was added 1 h before A
treatment. Cell-surface Awas removed using 0.25% trypsin/EDTA (In-
vitrogen). For binding assays, cells were incubated with FAM–A42 (2
M) or Alexa Fluor 488–RAP (100 nM) at 4°C for 2 h in PBS with 1.5%
FBS after suspension by cell dissociation solution, and subjected to
fluorescence-activated cell sorting (FACS) analysis.Only trace amount of
SDS-stable A42 oligomers and fibrils were detected in the media after
incubation under these conditions (supplemental Fig. 1, available at
www.jneurosci.org as supplemental material).
Kinetic analysis of endocytosis. Carrier-free [ 125I]Na was purchased
from PerkinElmer Life and Analytical Science. RAP and A42 (AnaSpec)
were iodinated using the IODO-GEN (Thermo Fisher Scientific) and the
Bolton-Hunter reagents (Thermo Fisher Scientific) according to the in-
structions of themanufacturer. N2a cells were plated onto 12-well dishes
and allowed to grow to 90% confluency. Cells were incubated with 10 nM
[125I]RAP or 100 nM [125I]A42 in binding buffer (DMEM containing
0.6% bovine serum albumin) at 4°C for 60 min. Cells were then incu-
bated at 37°C in binding buffer to initiate internalization. After each time
interval, cells were placed on ice, and the binding buffer was replaced
with ice-cold strip/stop solution (0.2 M acetic acid and 0.1 M NaCl, pH
2.6). Ligand remaining on the cell surface was stripped by incubation
with stop/strip solution for 20 min and counted. Cells were then solubi-
lized with low-SDS lysis buffer (62.5 mM Tris-HCl, pH 6.8, containing
0.2% SDS) and counted. The sum of radioactivity of ligands that were
internalized plus that remaining on the cell surface after each assay was
used as the maximum potential internalization. The fraction of internal-
ized ligand at each time point was calculated and plotted.
Western blotting for A. Samples containing A were electrophoreti-
cally separated on a 16%polyacrylamide Tris–tricine gels and transferred
to polyvinylidene difluoride membrane. Immunoblotting with 6E10 an-
tibody against A (0.5g/ml) was performed overnight at 4°C, followed
by the incubation with fluorescent anti-mouse IgG (1:10,000 dilution)
for 1 h at room temperature. Fluorescence signals were detected with an
Odyssey imaging scanner (LI-COR/Westburg).
Detection of cell-bound A by ELISA. Cells were incubated with A42
(50 nM) for 3 h at 4°C in PBS with 1.5% FBS after suspension by Cell
Dissociation Solution. After washing three times with PBS, cells were
dissolved in 5 M guanidine in 50 mM Tris-HCl, pH 8.0. Samples were
diluted 10-fold in DMEM and analyzed by sandwich ELISA for human
A42 (antibody 21F12), detected with biotin-conjugated antibody 3D6.
Statistical analysis.All quantified data represent an average of triplicate
samples. Error bars represent SD. Statistical significance was determined
by Student’s t test, and p 0.05 was considered significant.
Results
Both LRP1 and HSPG play roles in A uptake in GT1-7
neuronal cells
To investigate whether LRP1 and HSPG mediate cellular uptake
of A in neuronal cells, we used a mouse hypothalamic neuronal
cell line, GT1-7 cells (Liposits et al., 1991). Cells were transfected
with vehicle control or LRP1 siRNA and used for analysis 48 h
after transfection. Expression of LRP1 was significantly sup-
pressed by siRNA as confirmed by Western blotting (Fig. 1A).
Control or LRP1-suppressed GT1-7 cells were incubated with 20
nM Alexa Fluor 488-labeled RAP for 4 h at 37°C, followed by
treatment with Pronase to remove cell-surface RAP. Cell-
internalized RAP was assessed by FACS. RAP is a chaperone for
LDL receptor family members and tightly binds to LRP1 (Bu,
2001). Knockdown of LRP1 suppressed RAP internalization to
38% of the internalization for GT1-7 cells treated with vehicle
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control (Fig. 1B). When LRP1-
suppressed GT1-7 cells were incubated
with 500 nM FAM-labeled A42 for 24 h at
37°C, A42 internalization in LRP1-
suppressed cells was reduced to 69% of
the internalization for control cells (Fig.
1C). Although heparin did not affect RAP
internalization (Fig. 1B), it did inhibit
A42 internalization to 14% of that for
control cells (Fig. 1C). Importantly, hep-
arin further inhibited A42 internaliza-
tion in LRP1-suppressd GT1-7 cells (Fig.
1C), indicating that the role of HSPG in
A uptakemight be partially independent
of LRP1. To confirm the effects of LRP1
knockdown and heparin on A internal-
ization, control and LRP1-suppressed
GT1-7 cells were cultured with FAM–
A40 for 24 h at 37°C in the presence or
absence of heparin and analyzed by
confocal microscopy. Although cell-
associated A40 in LRP1-suppressed
GT1-7 cells was slightly decreased, hepa-
rin nearly eliminated A uptake in both
control and LRP1-suppressed GT1-7 cells
(Fig. 1D).
To confirm the effect of LRP1 knock-
down on A uptake in GT1-7 cells, we
restored LRP1 function by cotransfecting
an LRP1 minireceptor of domain IV,
mLRP4, which exhibits similar func-
tions to full-length LRP1 (Obermoeller-
McCormick et al., 2001). This mLRP4
does not contain an LRP1–siRNA target-
ing sequence and is therefore resistant to
knockdown by LRP1–siRNA. FACS analysis showed that mLRP4
expression restored FAM–A42 uptake in GT1-7 cells (Fig. 2A).
No significant differences in cell viability were detected after
knockdown of LRP1 by siRNA and mLRP4 transfection (trans-
fection efficiency, 52%) under these conditions (supplemental
Fig. 2, available at www.jneurosci.org as supplemental material).
To rule out cell-type-specific effects, we performed similar
FAM–A42 uptake experiments in MEF cells from both wild-
type (MEF1) and LRP1 knock-out mice (MEF2) (Fig. 2B). A
decrease in the internalization of FAM–A42 was observed in
MEF2 cells compared with MEF1. In addition, heparin further
inhibited A42 internalization in MEF2 cells, indicating that
LRP1 and HSPG are both involved in cellular A uptake in neu-
ronal and non-neuronal cells.
Increased A uptake in N2a cells overexpressing LRP1
depends on HSPG
We next investigated whether LRP1 overexpression enhances A
uptake. Because mouse neuroblastoma N2a cells express low lev-
els of endogenous LRP1 (Cuitino et al., 2005), they were stably
transfected with the LRP1 minireceptor mLRP4. Western blot-
ting revealed that mLRP4 wasmore effectively expressed in N2a–
mLRP4 cells compared with vector pcDNA3-transfected cells
(N2a–pcDNA3) (Fig. 3A). These cells were incubatedwith FAM–
A40 (500 nM) or FAM–A42 (500 nM) in the presence or absence
of heparin for 24 h at 37°C. FACS analysis showed that internal-
ization of A40 and A42 in N2a–mLRP4 cells increased to 2.4-
fold and 2.1-fold, respectively, compared with N2a–pcDNA3
cells (Fig. 3B,C). Interestingly, LRP1-mediated enhancement
of A uptake was inhibited by heparin (Fig. 3B,C) in a
concentration-dependent manner (Fig. 3D). Heparinase treat-
ment also decreased LRP1-mediated enhancement of cellular
A42 uptake (Fig. 3C). These results suggest that LRP1-mediated
uptake of A requires HSPG on the cell surface of N2a cells. To
Figure 1. LRP1 knockdown and heparin inhibit A uptake in GT1-7 cells. A, Western blotting using an anti-LRP1 antibody
showed that LRP1 expressionwas effectively suppressed by siRNA transfection.B, C, GT1-7 cells with or without LRP1 knockdown
by siRNAwere incubatedwith Alexa Fluor 488-RAP (20 nM;B) or FAM–A42 (500 nM; C) in the presence or absence of heparin (15
U/ml100g/ml). InternalizationofRAP (B) orA42 (C)wasanalyzedbyFACS. Error bars indicate SD fromthree independent
experiments.N.S., Not significant. **p0.01.D, The internalizationof FAM–A40 (500nM)wasanalyzedby confocalmicroscopy.
Left and right columns indicate FAM–A40 and merged images with Nomarski images, respectively.
Figure2. LRP1-mediated cellular uptakeof A in GT1-7 andMEF cells.A, LRP1minireceptor
mLRP4 or empty vector pcDNA3 was cotransfected with LRP1–siRNA into GT1-7 cells, and
cellular uptake of FAM–A42 (500 nM) after 24 h incubation was analyzed by FACS. LRP1
knockdown and mLRP4 overexpression were analyzed by Western blotting. B, MEF1 (wild-
type) and MEF2 (LRP1-deficient) cells were treated with 500 nM FAM–A42 in the presence or
absence of heparin (15 U/ml100g/ml) for 24 h; intracellular Awas then determined
by FACS. Error bars indicate SD from three independent experiments. **p 0.01.
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confirm the ability of LRP1 to promoteAuptake,N2a–pcDNA3
and N2a–mLRP4 cells were cultured with FAM–A42, and ana-
lyzed by confocal microscopy. When cells were incubated with
500 nM FAM–A42 for 24 h at 37°C, A42 internalization was
significantly higher in N2a–mLRP4 cells than in N2a–pcDNA3
cells. Internalized A42 was colocalized with LysoTracker. Con-
sistent with the results from FACS analysis, internalization of
A42 was almost eliminated by heparin (Fig. 3E). To determine
whether internalized A is degraded, N2a–pcDNA3 and N2a–
mLRP4 cells were incubated with 500 nM FAM–A42 in the pres-
ence or absence of heparin for 24 h at 37°C. The A-containing
media were then replaced with DMEM containing 10% FBS, and
the cells were incubated for an additional 24 h before analysis of
intracellular A42 by FACS (supplemental Fig. 3A, available at
www.jneurosci.org as supplemental material). Importantly, in-
ternalized A42 was cleared after 24 h of incubation in both N2a–
pcDNA3 and N2a–mLRP4 cells. When A42 clearance was
calculated under each condition, we found that it was enhanced
in N2a–mLRP4 cells compared with N2a–pcDNA3 cells. In ad-
dition, heparin inhibited this cellular clearance of A42 (supple-
mental Fig. 3B, available at www.jneurosci.org as supplemental
material).
HSPGs, but not LRP1, mediate A binding to neuronal cells
Next we investigated whether LRP1 and HSPG mediate binding
of A to neuronal cells. To analyze the role of HSPG in A bind-
ing, GT1-7 and N2a cells were incubated with 2 M FAM–A42
for 2 h at 4°C in the presence or absence of heparin. Thereafter,
A42 binding was assessed by FACS (Fig. 4A). Heparin signifi-
cantly inhibited the binding of A42 in a concentration-
dependent manner in both GT1-7 and N2a cells (Fig. 4A,B),
suggesting that cell-surface HSPGs constitute major A binding
sites on neuronal cells. However, neither LRP1 knockdown nor
LRP1 overexpression had any significant effect on A42 binding
in these neuronal cells (Fig. 4D). As a control, when LRP1-
suppressed GT1-7 cells or LRP1-overexpressing N2a–mLRP4
cells were incubated with Alexa Fluor 488-labeled RAP for 2 h at
4°C, knockdown of LRP1 suppressed RAP binding to 38% of
control cells, whereas LRP1 overexpression enhanced RAP bind-
ing to 2.2-fold of the N2a–pcDNA3 cells (Fig. 4C). Similar results
were obtained when A42 binding was analyzed by ELISA (sup-
plemental Fig. 4, available at www.jneurosci.org as supplemental
material). Together, these results indicate that HSPGs, but not
LRP1, play important roles in A binding to neuronal cells.
Figure 3. Heparin inhibits LRP1-mediated cellular uptake of A in N2a cells.A, N2a cells stably expressing a LRP1minireceptor (N2a–mLRP4) or vector control (N2a–pcDNA3)were analyzed for
LRP1 expressionusing ananti-LRP1 antibody.B,C, N2a–pcDNA3orN2a–mLRP4 cellswere incubatedwith FAM–A40 (500nM;B) or FAM–A42 (500nM;C), respectively, in thepresence or absence
of heparin (15 U/ml100g/ml) for 24 h at 37°C. Internalization of Awas analyzed by FACS. C, In some experiments, cells were treatedwith Heparinase I (Hep. I ).D, Various concentrations
of heparin (0.15 mU/ml to 15 U/ml) were incubated with N2a–pcDNA3 (open circles) and N2a–mLRP4 (filled circles) cells during their incubation with FAM–A42 (500 nM). Error bars indicate SD
from three independent experiments. **p 0.01. E, Internalization of FAM–A42 (500 nM)was analyzed by confocalmicroscopy. Left,middle, and right columns indicate FAM–A42, Lysotracker,
and merged images, respectively.
Figure4. Heparin inhibitsAbinding toneuronal cells.A, GT1-7orN2a cellswere incubated
withFAM–A42 (2M) in thepresenceor absenceofheparin (15U/ml100g/ml) for 2h
at 4°C. Binding of Awas analyzed by FACS.B, Various concentrations of heparin (1.5mU/ml to
150 U/ml) were usedwith GT1-7 (filled circles) or N2a (open circle) cells during their incubation
with FAM–A42 (2M). C, D, GT1-7 cells without or with LRP1 knockdown, N2a-pcDNA3, or
N2a–mLRP4 cells were incubated with Alexa Fluor 488–RAP (100 nM; C) or FAM–A42 (2M;
D) for 2 h at 4°C and analyzed by FACS. Error bars indicate SD from three independent experi-
ments. N.S., Not significant. **p 0.01.
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LRP1mediates A endocytosis in N2a cells
To compare the endocytosis rates of RAP and A, N2a–mLRP4
cells were first incubated with 10 nM [125I]RAP or 100 nM
[125I]A42 at 4°C for 1 h to allow binding to occur. Cells were
then warmed for different periods of time to allow ligand inter-
nalization and to determine endocytosis rates (Li et al., 2000).We
found that [125I]A42 had a slower rate of endocytosis than
[125I]RAP (Fig. 5A). Next, N2a–pcDNA3 and N2a–mLRP4 cells
were incubated with 100 nM [125I]A42 at 4°C for 1 h and then
warmed for different periods of time. Despite similar endocytosis
capacities, the initial endocytosis rate of [125I]A42 was faster in
N2a–mLRP4 cells than in N2a–pcDNA3 cells (Fig. 5B). These
results indicate that LRP1 plays an important role in mediating
A endocytosis in N2a cells; however, other mechanisms also
contribute to this process.
HSPG deficiency significantly decreases cellular A binding
and uptake
To further examine the role of HSPG in cellular A uptake, we
next used wild-type CHO-K1 cells, CHO-M1 cells deficient in
N-acetylglucosaminyltransferase/glucuronyltransferase (required
for HS biosynthesis) (Broekelmann et al., 2005), and CHO-745
cells deficient in xylosyltransferase [required for both HS and
chondroitin sulfate (CS) biosynthesis] (Esko et al., 1985). These
CHO cells were incubatedwith 500 nM FAM–A40 or FAM–A42
for 24 h at 37°C, and the uptake of A was assessed by FACS. We
found that internalization of both A40 and A42 in HS-deficient
CHO-M1 and HS/CS-deficient CHO-745 cells was significantly
lower than in wild-type CHO-K1 cells. Specifically, internaliza-
tion ofA40 inCHO-M1andCHO-745was 16 and 14%of that in
CHO-K1 cells, respectively (Fig. 6A). In the case of A42, A
uptake in CHO-M1 and CHO-745 was 16 and 5% of that in
CHO-K1 cells, respectively (Fig. 6B). The differences in A
internalization between CHO-M1 and CHO-745 cells were
significantly less than between CHO-K1 and CHO-M1 cells,
suggesting that HSPG is the predominant cell-surface proteogly-
can that mediates A uptake. Although heparin suppressed A42
internalization in CHO-K1 cells in a concentration-dependent
manner, it had little effect in CHO-M1 cells (Fig. 6C). To further
confirm the role of HSPG in A internalization, CHO cells were
cultured with FAM–A42 for 24 h at 37°C, and A uptake was
analyzed by confocal microscopy. Although cell-associated A42
in CHO-K1 cells was abundantly detected, very little internalized
A42 was detected in CHO-M1 and CHO-745 cells (Fig. 6D). To
analyze the roles of proteoglycans in A binding in these CHO
cells, they were incubated with 2 M FAM–A42 for 2 h at 4°C.
FACS analysis revealed that binding of A42 in CHO-M1 and
CHO-745 cells was also significantly lower than in CHO-K1 cells
(Fig. 6E). Collectively, these results clearly indicate that HSPG
plays critical roles in both A binding and uptake.
Heparin and LRP1 antibody inhibit A uptake in
primary neurons
To further determine the roles of HSPG and LRP1 in neuronal
A uptake, we analyzed the effects of heparin and an LRP1 block-
ing antibody on A uptake in mouse primary cortical neurons.
Neurons were incubated with FAM–A42 (500 nM) in the pres-
ence of heparin, non-immune IgG, or anti-LRP1 IgG for 4 h at
37°C and analyzed by confocal microscopy (Fig. 7A). When neu-
ronal cell bodies were observed by confocal microscopy, we
found that A42 internalization was suppressed by the treatment
of heparin and anti-LRP1 IgG. In contrast, non-immune IgG had
no effect on A42 uptake. Internalized A was partially colocal-
ized with a lysosomal marker, LysoTracker. Next, neurons were
incubated with 500 nM FAM–A42 for 1, 4, 8, or 24 h at 37°C in
the presence of heparin (Fig. 7B), non-immune IgG, or anti-
LRP1 IgG (Fig. 7C), followedby treatmentwith trypsin to remove
cell-surface A42. Cell-internalized A42 was assessed by FACS.
Although neurons effectively internalized A42 in a time-
dependentmanner, heparin significantly suppressedA42 uptake
(Fig. 7B), consistent with the results from confocal microscopy.
In addition, anti-LRP1 antibody significantly inhibited A42 in-
ternalization compared with non-immune IgG (Fig. 7C), albeit
to a lesser degree compared with heparin. Together, these results
indicate that both HSPG and LRP1 play critical roles in A up-
take in neurons.
Discussion
Intracellular or extracellular accumulation, aggregation, and
deposition of A in the brain are pathogenic events of AD
(Selkoe, 2001, 2002). One of themajor pathways for A clearance
is its cellular uptake and degradation by neurons, glia, and cells
along the brain vasculature (Bu, 2009). In this study, we focused
on investigating individual and cooperative roles of LRP1 and
HSPG in neuronal A uptake. Using complementary ap-
proaches, we showed that neuronal cell-surface HSPGs consti-
tute major A binding sites and are critical for A uptake.
Although not required for A binding, LRP1 cooperates with
HSPG in neuronal A uptake.
HSPG is composed of a core protein with long polysaccharide
chains of repeated heparan sulfate. There are two groups of
HSPGs: extracellular matrix HSPGs (e.g., perlecan, agrin, and
collagen XVIII) and cell-surface HSPGs (syndecan and glypican)
(van Horssen et al., 2003). Both extracellular matrix and cell-
surfaceHSPGswere detected by immunohistochemistry in senile
plaques, cerebral amyloid angiopathy, and neurofibrillary tangles
(van Horssen et al., 2003). These evidences strongly suggest that
HSPGs may interact with A and play some roles in AD patho-
genesis. Consistent with this notion, we demonstrated that hep-
arin binds to A (supplemental Fig. 5A, available at www.
jneurosci.org as supplementalmaterial) and significantly inhibits
neuronal A binding and uptake.Heparin binds to several classes
of extracellular proteins, including growth factors, matrix pro-
teins, and apolipoproteins (Bergamaschini et al., 2009). Heparan
sulfate was shown to bind to the amino acid 13–16 region
(HHQK) of A (Brunden et al., 1993) and to antagonize the
binding of A to HSPG in vitro (Castillo et al., 1997). To block
Figure 5. LRP1 regulates A endocytosis in N2a cells. A, N2a–mLRP4 cells were incubated
with 10 nM [ 125I]RAP (filled circles) or 100 nM [ 125I]A42 (open circles) for 1 h at 4°C and then
warmed to 37°C for the indicated times. B, N2a–pcDNA3 and N2a–mLRP4 cells were similarly
treated with 100 nM [ 125I]A42. The percentage of ligand internalized at each time interval is
equal to the amount of ligand internalized divided by the total cell-associated ligand. Error bars
indicate SD from three independent experiments. **p 0.01.
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Figure 7. Heparin and anti-LRP1 antibody inhibit cellular A uptake in primary neurons.A, Mouse primary cortical neuronswere incubatedwith FAM–A42 (500 nM) in the presence or absence
of heparin (15 U/ml100g/ml), non-immune IgG, or anti-LRP1 IgG (75g/ml) for 4 h at 37°C and analyzed by confocal microscopy. Non-immune IgG or anti-LRP1 IgGwas added 1 h before
A treatment. B, C, Internalization of A was analyzed by FACS after incubation with FAM–A42 (500 nM) for 1, 4, 8, and 24 h in the presence or absence of heparin (B) and in the presence of
non-immune IgG or anti-LRP1 IgG (C). Error bars indicate SD from three independent experiments. *p 0.05; **p 0.01.
Figure6. HSPGmediatesAuptakeandbinding. CHO-K1 (wild-type), CHO-M1 (HS-deficient), or CHO-745 (HS/CS-deficient) cellswere incubatedwith FAM–A40 (500nM;A) or FAM–A42 (500
nM;B) for 24 h at 37°C. Internalization of Awas analyzed by FACS. C, Various concentrations of heparin (0.15mU/ml to 15U/ml)were usedwith CHO-K1 (filled circles) or CHO-M1 (open circles) cells
during their incubation with FAM–A42 (500 nM). D, Internalization of FAM–A42 (500 nM) in CHO-K1, CHO-M1, or CHO-745 cells was analyzed by confocal microscopy. Left and right columns
indicate FAM–A42 andmerged images with Nomarski images, respectively. E, Cells were incubated with A42 (2M) for 3 h at 4°C, and binding of Awas analyzed by FACS. Error bars indicate
SD from three independent experiments. **p 0.01.
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heparin binding proteins and/or displaceHSPG binding proteins
at the cell surface, GT1-7 cells were pretreated with heparin and
then incubated with A42 after washing. No significant effect of
heparin pretreatment on A42 uptake was detected (supplemen-
tal Fig. 5B, available at www.jneurosci.org as supplemental mate-
rial), suggesting that heparin antagonizes the interaction of A to
HSPG through its binding toA. In addition,HSPGdeficiency in
CHO cells significantly decreased A binding and uptake.
Therefore, our findings indicate that A binding to neuronal
cell-surface HSPG may be the first and critical step for its
internalization, degradation, accumulation, and/or toxicity.
A binding to cell-surface and/or extracellular matrix HSPG
may also be important for its aggregation and eventual forma-
tion of amyloid plaques.
We showed that heparin suppresses A binding and internal-
ization in neuronal cell lines andmouse primary neurons. Similar
findings have been demonstrated in brain vascular smooth mus-
cle cell (Kanekiyo and Bu, 2009) and in microglia (Giulian et al.,
1998). However, heparin and heparinase treatment did not affect
A uptake in brain capillary endothelial cells (Yamada et al.,
2008). Because heparan sulfate biosynthesis differs depending on
tissue/cell types (Kreuger et al., 2006), the discrepancies in cellu-
lar A uptake may result from differences in tissue/cell-specific
HSPG structure. Several studies have demonstrated that heparin
and heparan sulfate suppress A cellular toxicity (Woods et al.,
1995; Bergamaschini et al., 2002), likely by inhibiting cellular A
binding and/or uptake. Cells internalize and degrade A through
the lysosomal pathway (Hu et al., 2009). We demonstrated that
LRP1 and HSPGmediate uptake of A to lysosomes and its sub-
sequent cellular clearance in N2a cells. However, when the
capacity is overwhelmed through continuous exposure to high
concentrations of extracellular A, intracellular accumulation
and aggregation of Amay be induced, leading to cellular toxic-
ity. We recently showed that enhancement of A uptake through
LRP1 leads to eventual lysosomal accumulation and slightly de-
creased cell viability when cells were exposed to high A concen-
trations and long periods of incubation (Fuentealba et al., 2010).
Furthermore, the remnants of these aggregates after cell death
may induce extracellular amyloid plaque formation through its
seeding effect (Hu et al., 2009). In this view, heparin and heparin-
like compounds may be promising candidates for AD therapy
because of their competitive function against HSPGs. Bergam-
aschini et al. (2004) demonstrated that the effect of long-term,
peripheral treatment with a low-molecular-weight heparin sig-
nificantly decreased A concentration and deposition in the
brain of APP transgenic mice (Bergamaschini et al., 2004).
LRP1 plays critical roles in cellular A uptake in the brain.
Harris-White et al. (2004) showed that TGF2-mediated intran-
euronal accumulation of brain-injected A depends on LRP1
function (Harris-White et al., 2004). We showed that the inter-
nalization of A was also decreased in LRP1-deficient neuronal
cells and increased in LRP1-overexpressing neuronal cells. LRP1
expression restored A uptake in LRP1 knocked down GT1-7
cells. We also demonstrated that treatment with a neutralizing
antibody to LRP1 decreasedAuptake inmouse primary cortical
neuron. In addition, LRP1 enhanced the A endocytosis rate in
N2a cells. Importantly, LRP1-mediated A uptake was also in-
hibited by heparin, indicating that the function of LRP1 in cellu-
lar A uptake depends on HSPG. In contrast to HSPG, we
showed that neither LRP1 knockdown nor overexpression affects
A binding. These results can be explained by two possibilities.
First, HSPG may function as a coreceptor for LRP1. Previous
work has shown that LRP1 forms a complex with HSPG (Wilsie
and Orlando, 2003). Amay initially bind to the HSPG sites on
the surface of the complex and thenmay undergo endocytosis via
LRP1, in a process analogous to another LRP1 ligand, coagula-
tion factor VIII (Sarafanov et al., 2001). We have shown that
inhibition of LRP1 endocytosis decreases cellular A uptake in
N2a cells (Fuentealba et al., 2010). LRP1 is a large endocytotic
receptor that recognizes 30 ligands, including lipoproteins,
proteinases, proteinase inhibitor complexes, extracellular matrix
proteins, bacterial toxins, viruses, and various intracellular pro-
teins (Herz and Strickland, 2001; Bu, 2009). Although the ligand-
binding sites on LRP1 localize primarily on domains II and IV
(Herz and Strickland, 2001), some LRP1 ligands seem to require
coreceptors for their interaction (Nykjaer et al., 1992; Sarafanov
et al., 2001). Awas shown to bind directly to domains II and IV
of LRP1 (Sagare et al., 2007); however, another study did not
support direct A binding to LRP1 (Yamada et al., 2008). Our
results suggest that HSPG may be one of the candidate corecep-
tors of LRP1 for A binding and uptake.
We showed that A had a slower rate of endocytosis than RAP
in N2a–mLRP4 cells, indicating that LRP1 mediates A endocy-
tosis throughdifferentmechanisms from its other ligands. There-
fore, the other possibility is that HSPG, which is abundantly
expressed in neurons, may capture A on the cell surface and
subsequently internalize A through an LRP1-regulated signal-
ing pathway. Increasing evidence also shows that LRP1 functions
as a signal-transducing receptor (Herz and Strickland, 2001) and
that LRP1 plays a critical role in neuronal viability by regulating
key survival signaling pathways (Fuentealba et al., 2009). In ad-
dition, LRP1 regulates cell migration (Song et al., 2009) and the
integrity of the blood–brain barrier (Yepes et al., 2003). A bind-
ing to HSPG may activate LRP1 signaling pathways, resulting in
an enhancement of cellular A uptake. Consistent with an LRP1-
mediated signaling function, actin polymerization, which is crit-
ical for macropinocytosis and A uptake (Mandrekar et al.,
2009), is impaired in LRP1-deficient cells (Zhou et al., 2009). This
evidence suggests that LRP1 may mediate A cellular uptake by
regulating macropinocytosis.
In summary, we have demonstrated that HSPG and LRP1
function cooperatively in neuronal A binding and uptake. We
show thatHSPGmediates A binding on the cell surface and that
both HSPG and LRP1 play important roles in A uptake. Our
findings provide novel insights into the molecular mechanisms
of AD pathogenesis. Additional studies of the HSPG/LRP1-
mediatedA pathwaysmay lead to novel therapeutic strategies to
treat AD.
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